Condition: Hepatocholangiocarcinoma · Fibrolamellar Carcinoma · Hepatic Epithelioid Hemangioendothelioma · Sponsor: Federation Francophone de Cancerologie Digestive
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.
This description comes directly from the study's public registry record.
lila gaba · 06 99 78 84 73 · lila.gaba@u-bourgogne.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens picardie | Amiens, France | Recruiting |
| Chu Angers | Angers, France | Recruiting |
| Ch - Centresimone Veil de Beauvais | Beauvais, France | Recruiting |
| Chu Jean Minjoz | Besançon, France | Not Yet Recruiting |
| Ch Bethune Beuvry | Béthune, France | Not Yet Recruiting |
| Avicenne | Bobigny, France | Recruiting |
| Cote de Nacre | Caen, France | Not Yet Recruiting |
| Centre Hospitalier | Calais, France | Recruiting |
| Chu de Clichy Hopital Beaujon | Clichy, France | Recruiting |
| Centre Hospitalier Universitaire Henri Mondor | Créteil, France | Recruiting |
| CHU | Dijon, France | Recruiting |
| Chu Grenobles Alpes | La Tronche, France | Recruiting |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06541652